Citius Pharmaceuticals Inc (CTXR)

Name: Citius Pharmaceuticals Inc Financial Statements
Creator: Quarter Results

Healthcare | Biotechnology

Latest reporting period: 2025-12-31

Latest Quarter

2025-12-31

Revenue

$3.9M

Net Income

-$8.2M

Operating Margin

-228.7%

Free Cash Flow

-$26.6M

Debt / Assets

40.8%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Citius Pharmaceuticals Inc (CTXR).
Income Statement (Quarterly)	2025-12-31	2025-03-31	2024-12-31	2024-09-30
Revenue	3,944,111	0	0	155,926
Cost of Revenue	1,362,646	0	0	155,926
Gross Profit	2,581,465	0	0	0
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	5,720,727	4,792,122	5,387,752	8,135,550
Operating Expenses	11,600,673	11,260,678	10,039,614	11,050,478
Operating Income	-9,019,208	0	-10,039,614	-11,050,478
Interest Expense	155,538	0	0	0
Income Before Tax	-9,129,649	-11,247,265	-10,017,006	-10,933,164
Income Tax Expense	264,240	264,240	264,240	144,000
Net Income	-8,220,784	-11,511,505	-9,768,246	-10,790,164
Per Share
EPS	-0.38	-0.07	-0.06	-0.06
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Citius Pharmaceuticals Inc (CTXR).
Income Statement (Annual)	2025-09-30	2024-09-30	2023-09-30	2022-09-30	2021-09-30
Revenue	0	0	0	0	0
Cost of Revenue	214,250	209,611	194,316	179,677	0
Gross Profit	-214,250	-209,611	-194,316	-179,677	0
Operating Expenses
R&D Expenses	0	0	0	0	0
SG&A Expenses	18,532,843	18,249,402	21,912,289	15,660,563	11,291,391
Operating Expenses	38,311,358	41,995,681	36,537,702	33,316,045	23,531,894
Operating Income	-38,525,608	-41,995,681	-36,732,018	-33,316,045	-23,531,894
Interest Expense	267,782	0	0	251,399	10,839
Income Before Tax	-38,683,309	-38,849,839	-31,966,912	-33,064,646	-23,054,434
Income Tax Expense	1,056,960	576,000	576,000	576,000	0
Net Income	-37,433,911	-39,138,839	-32,542,912	-33,640,646	-23,054,434
Per Share
EPS	-3.38	-5.97	-0.22	-0.23	-0.23
EPS Diluted	0.00	0.00	0.00	0.00	0.00

Balance sheet quarterly history for Citius Pharmaceuticals Inc (CTXR).
Balance Sheet (Quarterly)	2025-09-30	2024-09-30	2023-09-30	2022-09-30
Assets
Cash and Cash Equivalents	4,252,290	3,251,880	26,480,928	41,711,690
Short Term Investments	0	0	0	0
Net Receivables	0	0	0	0
Inventory	22,286,693	8,268,766	0	0
Total Current Assets	27,934,473	14,220,646	34,370,434	44,564,270
Property Plant Equipment	818,694	246,247	455,858	650,174
Goodwill and Intangibles	102,146,796	102,146,796	68,746,796	68,746,796
Total Assets	130,938,025	116,651,751	103,611,150	113,999,302
Liabilities
Account Payables	13,693,692	4,927,211	2,927,334	1,165,378
Short Term Debt	1,088,348	241,547	218,380	196,989
Total Current Liabilities	44,914,740	35,814,803	5,778,997	4,530,012
Long Term Debt	1,449,850	21,318	262,865	481,245
Total Liabilities	53,410,425	42,549,921	12,179,662	10,573,057
Shareholders Equity
Retained Earnings	-238,804,129	-201,370,218	-162,231,379	-129,688,467
Total Shareholders Equity	67,550,178	70,077,450	90,831,108	102,825,865

Balance sheet annual history for Citius Pharmaceuticals Inc (CTXR).
Balance Sheet (Annual)	2025-09-30	2024-09-30	2023-09-30	2022-09-30	2022-06-30
Assets
Cash and Cash Equivalents	4,252,290	3,251,880	26,480,928	41,711,690	48,044,194
Short Term Investments	0	0	0	0	0
Net Receivables	0	0	0	0	0
Inventory	22,286,693	8,268,766	0	0	0
Total Current Assets	27,934,473	14,220,646	34,370,434	44,564,270	50,834,513
Property Plant Equipment	818,694	246,247	455,858	650,174	696,424
Goodwill and Intangibles	102,146,796	102,146,796	68,746,796	68,746,796	9,346,796
Total Assets	130,938,025	116,651,751	103,611,150	113,999,302	120,315,795
Liabilities
Account Payables	13,693,692	4,927,211	2,927,334	1,165,378	1,690,520
Short Term Debt	1,088,348	241,547	218,380	196,989	191,902
Total Current Liabilities	44,914,740	35,814,803	5,778,997	4,530,012	4,461,122
Long Term Debt	1,449,850	21,318	262,865	481,245	532,883
Total Liabilities	53,410,425	42,549,921	12,179,662	10,573,057	9,979,805
Shareholders Equity
Retained Earnings	-238,804,129	-201,370,218	-162,231,379	-129,688,467	-121,697,727
Total Shareholders Equity	67,550,178	70,077,450	90,831,108	102,825,865	109,735,610

Cash flow quarterly history for Citius Pharmaceuticals Inc (CTXR).
Cash Flow Statement (Quarterly)	2025-09-30	2024-09-30	2023-09-30	2022-12-31
Operating Activities
Net Income	-39,740,269	-39,425,839	-32,542,912	-3,593,645
Depreciation & Amortization	214,250	209,611	194,316	47,187
Stock Based Compensation	10,836,291	11,839,678	6,718,705	344,763
Change in Working Capital	1,053,430	-1,685,001	-4,006,321	-1,766,744
Operating Cash Flow	-26,552,738	-28,201,375	-29,060,212	-4,824,439
Investing Activities
Capital Expenditure	0	0	2	0
Investments	-5,750,000	0	2	0
Investing Cash Flow	-5,750,000	-5,000,000	0	0
Financing Activities
Debt Repayment	1,000,000	0	0	0
Common Stock Issued/Repurchased	32,303,148	13,803,684	13,798,183	0
Dividends Paid	0	0	0	0
Financing Cash Flow	33,303,148	9,972,327	13,829,450	0
Summary
Free Cash Flow	-26,552,738	-28,201,375	-29,060,210	-4,824,439
Net Change in Cash	1,000,410	-23,229,048	-15,230,762	-33,185,695

Cash flow annual history for Citius Pharmaceuticals Inc (CTXR).
Cash Flow Statement (Annual)	2025-09-30	2024-09-30	2023-09-30	2022-12-31	2022-09-30
Operating Activities
Net Income	-39,740,269	-39,425,839	-32,542,912	-3,593,645	-33,640,646
Depreciation & Amortization	214,250	209,611	194,316	47,187	179,677
Stock Based Compensation	10,836,291	11,839,678	6,718,705	344,763	3,905,954
Change in Working Capital	1,053,430	-1,685,001	-4,006,321	-1,766,744	239,555
Operating Cash Flow	-26,552,738	-28,201,375	-29,060,212	-4,824,439	-28,361,256
Investing Activities
Capital Expenditure	0	0	2	0	0
Investments	-5,750,000	0	2	0	0
Investing Cash Flow	-5,750,000	-5,000,000	0	0	0
Financing Activities
Debt Repayment	1,000,000	0	0	0	0
Common Stock Issued/Repurchased	32,303,148	13,803,684	13,798,183	0	0
Dividends Paid	0	0	0	0	0
Financing Cash Flow	33,303,148	9,972,327	13,829,450	0	0
Summary
Free Cash Flow	-26,552,738	-28,201,375	-29,060,210	-4,824,439	-28,361,256
Net Change in Cash	1,000,410	-23,229,048	-15,230,762	-33,185,695	-28,361,256